US · TLPH
Talphera, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- San Mateo, CA 94404
- Website
- talphera.com
Price · as of 2024-12-31
$0.92
Market cap 18.7M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.90 | +3,699.26% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $63.40 | ||||
| 2011 | $72.20 | ||||
| 2012 | $98.20 | $109.65 | $6.56 | $0.00 | $0.00 |
| 2013 | $238.40 | $904.08 | $35.18 | $0.00 | $0.00 |
| 2014 | $81.20 | $1,622.65 | $11.30 | $0.00 | $1,286.75 |
| 2015 | $72.40 | $347.06 | $256,094.45 | $0.00 | $0.00 |
| 2016 | $64.00 | $33.77 | $0.50 | $0.00 | $23.69 |
| 2017 | $42.00 | $16.80 | $0.00 | $0.00 | $956.29 |
| 2018 | $65.40 | $32.30 | $0.00 | $0.00 | $996.05 |
| 2019 | $28.60 | $22.73 | $0.00 | $0.00 | $0.00 |
| 2020 | $44.40 | $51.46 | $3.63 | $0.00 | $0.00 |
| 2021 | $6.80 | $28.62 | $0.00 | $0.00 | $473.37 |
| 2022 | $1.18 | $74.62 | |||
| 2023 | $1.13 | $0.00 | $0.00 | ||
| 2024 | $0.55 | $34.90 |
AI valuation
Our deep-learning model estimates Talphera, Inc.'s (TLPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.90
- Current price
- $0.92
- AI upside
- +3,699.26%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TLPH | Talphera, Inc. | $0.92 | 18.7M | +3,699% | — | — | — | -1.09 | 1.78 | — | -0.78 | — | 1.78 | 0.00% | — | — | -117.65% | -293.62% | -67.32% | 0.82 | -38.71 | 3.56 | 3.35 | 0.15 | -6124.00% | -10000.00% | -2790.00% | -89.22% | -4.79 | -244.16% | 0.00% | 0.00% | 0.00% | -0.78 | -0.94 | — | -36.58 |
| COSM | Cosmos Health Inc. | $0.39 | 10.71M | +8,441% | +650% | — | — | -0.61 | 0.40 | 0.18 | -1.53 | — | 0.59 | 7.92% | -28.56% | -29.73% | -53.43% | -38.56% | -26.90% | 0.48 | -15.36 | 0.99 | 0.63 | -0.83 | -4558.00% | 197.00% | -6720.00% | -82.82% | -0.30 | -20.18% | 63.07% | -38.30% | 63.07% | -1.37 | -2.62 | 0.39 | -2.69 |
| IBIO | iBio, Inc. | $2.82 | 44.53M | +1,048% | -88% | — | — | -0.48 | 0.59 | 22.05 | -0.22 | — | 1.10 | 100.00% | -4650.50% | -4594.25% | -101.52% | -174.01% | -70.79% | 0.24 | -87.75 | 1.59 | 1.42 | 0.30 | -7308.00% | 7778.00% | -1835.00% | -173.71% | -2.51 | -143.31% | 0.00% | 0.00% | 0.00% | -0.20 | -0.24 | 9.36 | -21.87 |
| INTS | Intensity Therapeutics, I… | $7.66 | 14.45M | — | — | — | — | -1.89 | 10.53 | — | -1.74 | — | 10.53 | 0.00% | — | — | -202.34% | 3350.51% | -147.37% | 0.05 | — | 1.92 | 1.48 | 0.15 | -1522.00% | — | 11124.00% | -49.52% | -8.67 | 3074.75% | 0.00% | 0.00% | 0.00% | -1.71 | -1.86 | — | -20.70 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| MIRA | MIRA Pharmaceuticals, Inc… | $1.27 | 53.18M | — | — | — | — | -1.99 | 7.09 | — | -1.59 | — | 7.09 | 0.00% | — | — | -238.90% | 1872.70% | -199.93% | 0.00 | -48.40 | 3.99 | 3.92 | 0.35 | -2154.00% | — | 2269.00% | -35.65% | -7.69 | 1298.69% | 0.00% | 0.00% | 0.00% | -1.59 | -2.30 | — | -9.18 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| PIII | P3 Health Partners Inc. | $2.12 | 6.93M | +1,116% | +75% | — | — | -0.09 | 0.35 | 0.02 | -0.78 | -0.11 | -0.05 | 100.00% | -21.37% | -9.05% | -284.66% | -147.86% | -37.75% | 2.19 | -14.46 | 0.37 | 0.33 | -0.64 | 7758.00% | 1848.00% | 4145.00% | -409.98% | -0.22 | -50.78% | 0.00% | 0.00% | 0.00% | -0.48 | -1.40 | 0.10 | -0.79 |
| SCYX | SCYNEXIS, Inc. | $0.75 | 31.47M | +6,873% | -20% | — | +4,875% | -2.21 | 0.85 | 12.54 | -0.21 | — | 0.85 | 100.00% | -990.84% | -568.29% | -33.25% | -288.55% | -19.44% | 0.30 | -14.53 | 3.00 | 2.89 | -0.01 | -13165.00% | -9733.00% | -13991.00% | -51.13% | -1.00 | -186.64% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 1.05 | -5.70 |
About Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
- CEO
- Vincent J. Angotti
- Employees
- 13
- Beta
- 0.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.92) − 1 = — (DCF, example).